Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harrison, L. C.
Right arrow Articles by Martin, F. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harrison, L. C.
Right arrow Articles by Martin, F. I.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 34, Issue 12 1306-1308, Copyright © 1985 by American Diabetes Association

ARTICLES

Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine

LC Harrison, PG Colman, B Dean, R Baxter and FI Martin

Azathioprine (2 mg/kg) was given, in addition to routine insulin treatment, to alternate patients presenting with recent-onset type I diabetes. Treated (N = 13) and untreated (N = 11) patients did not differ significantly at diagnosis with respect to age, duration of symptoms, body weight, blood glucose, hemoglobin A1c, or presence of ketosis. Eight patients were treated for 12 mo, three elected to stop treatment at 6 mo, and treatment was stopped in two because of side effects. Seven treated patients had a remission compared with one untreated patient. At 12 mo these seven patients were distinguished by significantly higher basal and glucagon-stimulated levels of C-peptide (1.98 +/- 0.52 and 3.88 +/- 0.34 micrograms/L, respectively) compared with the other six treated patients (0.93 +/- 0.52 and 1.32 +/- 0.85 microgram/L, respectively), and by the persistence of islet cell cytoplasmic antibodies. Remissions were not sustained in the 1-2 yr after treatment, although relapsed patients required less insulin for control. These results corroborate those from nonrandomized trials using cyclosporine and suggest that protracted treatment with nonspecific immunosuppressive drugs may be necessary to avert insulin dependence.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
J. C. Voltarelli, C. E. B. Couri, A. B. P. L. Stracieri, M. C. Oliveira, D. A. Moraes, F. Pieroni, M. Coutinho, K. C. R. Malmegrim, M. C. Foss-Freitas, B. P. Simoes, et al.
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
JAMA, April 11, 2007; 297(14): 1568 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
J. Ernerudh, J. Ludvigsson, G. Berlin, and U. Samuelsson
Effect of Photopheresis on Lymphocyte Population in Children with Newly Diagnosed Type 1 Diabetes
Clin. Vaccine Immunol., September 1, 2004; 11(5): 856 - 861.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. J. Greenbaum and L. C. Harrison
Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes
Diabetes, May 1, 2003; 52(5): 1059 - 1065.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
J Ludvigsson, U Samuelsson, J Ernerudh, C Johansson, L Stenhammar, and G Berlin
Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial
Arch. Dis. Child., August 1, 2001; 85(2): 149 - 154.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1985 by the American Diabetes Association.